NYSEAMERICAN:PFNX - Pfenex Stock Price, News & Analysis

$10.06
+0.40 (+4.14 %)
(As of 09/17/2019 11:25 AM ET)
Today's Range
$9.52
Now: $10.0599
$10.20
50-Day Range N/A
52-Week Range
$3.13
Now: $10.0599
$10.16
Volume88,593 shs
Average Volume156,511 shs
Market Capitalization$317.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$317.87 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.


Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.07. The biotechnology company earned $2.81 million during the quarter, compared to analyst estimates of $5.65 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

3 equities research analysts have issued 12-month target prices for Pfenex's stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Pfenex's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

Media coverage about PFNX stock has been trending negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfenex earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Pfenex.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Relypsa (RLYP), Ocular Therapeutix (OCUL), Opko Health (OPK), Verastem (VSTM), Alder Biopharmaceuticals (ALDR), CTI BioPharma (CTIC), DryShips (DRYS), Fate Therapeutics (FATE), Incyte (INCY) and Rigel Pharmaceuticals (RIGL).

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.23%), Renaissance Technologies LLC (4.46%), Vanguard Group Inc. (3.97%), Park West Asset Management LLC (2.70%), Russell Investments Group Ltd. (1.18%) and Northern Trust Corp (1.07%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Park West Asset Management LLC, Russell Investments Group Ltd., Strs Ohio, AXA, Invesco Ltd., Falcon Point Capital LLC and Susquehanna International Group LLP. View Insider Buying and Selling for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, JPMorgan Chase & Co., Jacobs Levy Equity Management Inc., Grantham Mayo Van Otterloo & Co. LLC and Jefferies Group LLC. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $10.07.

How big of a company is Pfenex?

Pfenex has a market capitalization of $318.19 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel